Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients with Newly Diagnosed or Recurrent Glioblastoma
CLTR 1314 | 14-483
Disease(s): Brain, Glioblastoma
See full trial information
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations
ZNCA 1114 | 14-656
Disease(s): Breast cancer
See full trial information
Safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of open-label study with multiple and (for non-responders) escalating subcutaneous doses of BI 655064 once a week in patients with chronic primary immune thrombocytopenic purpura
BIP 1Z14 | 15-042
Disease: Chronic Immune Thrombocytopenic Purpura
See full trial information
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
AGSP 1Z14 | 15-124
Disease: Hematologic Malignancy, Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
See full trial information
A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)
SEGE 1914 | 15-144
Disease(s): Leukemia, Acute Myeloid (AML)
See full trial information
A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
KARY 1414 | 14-1340
Disease: Lymphoma
See full trial information
A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
NCI 1615 | 15-119
Disease(s): Melanoma
See full trial information
A Phase 3, Study of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib
GSI 3Z14 | 15-048
Disease(s): Myelofibrosis
See full trial information
A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
BIP 1914 | 14-1163
Disease(s): Myelodysplastic Syndrome (MDS)
See full trial information
A Phase 2, double-blind, randomized safety and efficacy study of PF-04449913 versus placebo with defined best supportive therapy allowed in both arms in patients with Myelofibrosis previously treated with one or more Janus kinase inhibitors
PFIZ 1Z14 | 14-1326
Disease: Myelofibrosis
See full trial information
TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation
CLVS 1514 | 14-775
Disease(s): Non-small cell lung cancer (NSCLC)
See full trial information
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
